Literature DB >> 25730188

Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome.

I Aldoss1, A Dagis2, J Palmer2, S Forman1, V Pullarkat1.   

Abstract

Mesh：

Year:  2015        PMID： 25730188     DOI： 10.1038/bmt.2015.8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

Authors:  Sonali M Smith; Michelle M Le Beau; Dezheng Huo; Theodore Karrison; Ronald M Sobecks; John Anastasi; James W Vardiman; Janet D Rowley; Richard A Larson
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

2.  Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?

Authors:  Guilin Tang; Zhuang Zuo; Deborah A Thomas; Pei Lin; Dingsheng Liu; Ying Hu; Hagop M Kantarjian; Carlos Bueso-Ramos; L Jeffrey Medeiros; Sa A Wang
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

3.  Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification.

Authors:  Frederick Racke; Carol Cole; Alison Walker; Jeffrey Jones; Nyla A Heerema
Journal:  Cancer Genet       Date:  2012-12-11

Review 4.  Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review.

Authors:  Wei Chen; Endi Wang; Ying Lu; Karl K Gaal; Qin Huang
Journal:  Am J Clin Pathol       Date:  2010-01       Impact factor: 2.493

5.  Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

Authors:  L Pagano; A Pulsoni; M E Tosti; L Annino; A Mele; A Camera; B Martino; C Guglielmi; R Cerri; E Di Bona; R Invernizzi; C Castagnola; R Bassan; L Mele; G Todeschini; G Leone; F Mandelli
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

6.  Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.

Authors:  Michael G Kiehl; Ludwig Kraut; Rainer Schwerdtfeger; Bernd Hertenstein; Mats Remberger; Nicolaus Kroeger; Mathias Stelljes; Martin Bornhaeuser; Hans Martin; Christoph Scheid; Arnold Ganser; Axel R Zander; Joachim Kienast; Gerhard Ehninger; Dieter Hoelzer; Volker Diehl; Axel A Fauser; Olle Ringden
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities.

Authors:  S Ishizawa; M L Slovak; L Popplewell; V Bedell; J E Wrede; N H Carter; D S Snyder; D A Arber
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

8.  Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases.

Authors:  R Shivakumar; W Tan; G E Wilding; E S Wang; M Wetzler
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976

9.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Authors:  Anthony H Goldstone; Susan M Richards; Hillard M Lazarus; Martin S Tallman; Georgina Buck; Adele K Fielding; Alan K Burnett; Raj Chopra; Peter H Wiernik; Letizia Foroni; Elisabeth Paietta; Mark R Litzow; David I Marks; Jill Durrant; Andrew McMillan; Ian M Franklin; Selina Luger; Niculae Ciobanu; Jacob M Rowe
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113

10.  AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.

Authors:  Claudia Schoch; Susanne Schnittger; Mirjam Klaus; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113
  10 in total
  12 in total

1.  Therapy-related acute lymphoblastic leukemia.

Authors:  Josep-Maria Ribera
Journal:  Haematologica       Date:  2018-10       Impact factor: 9.941

2.  Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature.

Authors:  Pengfei Liu; Peiwen Li; Ting Lei; Limei Qu; Haiyan Huang; Qingchun Mu
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

Review 3.  Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

Authors:  Francesca Ferraro; Feng Gao; Keith Stockerl-Goldstein; Peter Westervelt; John F DiPersio; Armin Ghobadi
Journal:  Leuk Res       Date:  2018-07-31       Impact factor: 3.156

Review 4.  Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Acute Leukemia.

Authors:  Ram Vasudevan Nampoothiri; Auro Viswabandya
Journal:  Indian J Hematol Blood Transfus       Date:  2020-08-12       Impact factor: 0.915

5.  Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.

Authors:  Ibrahim Aldoss; Marzia Capelletti; Jihye Park; Romanos Sklavenitis Pistofidis; Raju Pillai; Tracey Stiller; James F Sanchez; Stephen J Forman; Irene M Ghobrial; Amrita Krishnan
Journal:  Leukemia       Date:  2018-07-19       Impact factor: 11.528

6.  Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer.

Authors:  Marie Joelle Jabagi; Anthony Goncalves; Norbert Vey; Thien Le Tri; Mahmoud Zureik; Rosemary Dray-Spira
Journal:  Cancers (Basel)       Date:  2019-09-29       Impact factor: 6.639

7.  Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.

Authors:  Caner Saygin; Ashwin Kishtagari; Ryan D Cassaday; Natalie Reizine; Ilana Yurkiewicz; Michaela Liedtke; Wendy Stock; Richard A Larson; Ross L Levine; Martin S Tallman; Jae H Park; Cassandra Kerr; Bartlomiej Przychodzen; Mikkael A Sekeres; Matt E Kalaycio; Hetty E Carraway; Betty K Hamilton; Ronald Sobecks; Aaron Gerds; Sudipto Mukherjee; Aziz Nazha; Jaroslaw P Maciejewski; Anjali S Advani
Journal:  Blood Adv       Date:  2019-12-23

8.  Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance.

Authors:  A S Rosenberg; A Brunson; J K Paulus; J Tuscano; T Wun; T H M Keegan; B A Jonas
Journal:  Blood Cancer J       Date:  2017-09-08       Impact factor: 11.037

9.  Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.

Authors:  Ibrahim Aldoss; Tracey Stiller; Ni-Chun Tsai; Joo Y Song; Thai Cao; N Achini Bandara; Amandeep Salhotra; Samer Khaled; Ahmed Aribi; Monzr M Al Malki; Matthew Mei; Haris Ali; Ricardo Spielberger; Margaret O'Donnell; David Snyder; Thomas Slavin; Ryotaro Nakamura; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Haematologica       Date:  2018-06-14       Impact factor: 9.941

10.  Synchronous B-Cell Acute Lymphoblastic Leukemia and Serous Ovarian Carcinoma: A Case Report.

Authors:  Michael Superdock; Justin Komisarof; Hani Katerji; Eric Huselton
Journal:  Case Rep Oncol       Date:  2021-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.